Cargando…
Framework humanization optimizes potency of anti-CD72 nanobody CAR-T cells for B-cell malignancies
BACKGROUND: Approximately 50% of patients who receive anti-CD19 CAR-T cells relapse, and new immunotherapeutic targets are urgently needed. We recently described CD72 as a promising target in B-cell malignancies and developed nanobody-based CAR-T cells (nanoCARs) against it. This cellular therapy de...
Autores principales: | Temple, William C, Nix, Matthew A, Naik, Akul, Izgutdina, Adila, Huang, Benjamin J, Wicaksono, Gianina, Phojanakong, Paul, Serrano, Juan Antonio Camara, Young, Elizabeth P, Ramos, Emilio, Salangsang, Fernando, Steri, Veronica, Xirenayi, Simayijiang, Hermiston, Michelle, Logan, Aaron C, Stieglitz, Elliot, Wiita, Arun P |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10680002/ https://www.ncbi.nlm.nih.gov/pubmed/38007238 http://dx.doi.org/10.1136/jitc-2023-006985 |
Ejemplares similares
-
Bifunctional iRGD-anti-CD3 enhances antitumor potency of T cells by facilitating tumor infiltration and T-cell activation
por: Zhou, Shujuan, et al.
Publicado: (2021) -
Severe cytopenia after CD19 CAR T-cell therapy: a retrospective study from the EBMT Transplant Complications Working Party
por: Penack, Olaf, et al.
Publicado: (2023) -
Bone marrow MSC from pediatric patients with B-ALL highly immunosuppress T-cell responses but do not compromise CD19-CAR T-cell activity
por: Zanetti, Samanta Romina, et al.
Publicado: (2020) -
Point mutation in CD19 facilitates immune escape of B cell lymphoma from CAR-T cell therapy
por: Zhang, Zhen, et al.
Publicado: (2020) -
Adherent cell depletion promotes the expansion of renal cell carcinoma infiltrating T cells with optimal characteristics for adoptive transfer
por: Braun, Mitchell W, et al.
Publicado: (2020)